Quantcast
Last updated on April 18, 2014 at 9:14 EDT

Latest Catecholamines Stories

2013-08-13 08:30:42

TORONTO, Aug. 13, 2013 /PRNewswire/ -- While we all have "off" periods, those who suffer from Parkinson's--a progressive neurodegenerative disease--experience a different kind of off time. A significant fraction of those with the disease often wake up in a rigid or frozen state with impaired movement and/or inability to speak. This most often occurs on waking, when their last dose of levodopa + carbidopa ("L-dopa")--taken before bedtime--has long since worn off. Add to this that the...

Alcoholism Risk May Be Driven By Overactive Dopamine System
2013-08-11 04:44:39

redOrbit Staff & Wire Reports - Your Universe Online Individuals who are vulnerable to alcoholism could experience an abnormally large response in the brain’s reward-seeking pathways when they drink, according a new study appearing in the January issue of Alcoholism: Clinical & Experimental Research. Marco Leyton, a professor of psychiatry at McGill University in Montreal and corresponding author of the study, and his colleagues report when compared to those at low risk of...

2013-07-11 20:20:56

NEW YORK, July 11, 2013 /PRNewswire-USNewswire/ -- Research projects from five biopharmaceutical companies in the United States, Canada and Israel comprise the 2013 first half (1H 2013) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting...

2013-06-19 08:29:22

NESS ZIONA, Israel, June 19, 2013 /PRNewswire/ -- NeuroDerm, Ltd. today announced that results from a phase I study in volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, were presented at the 2013 International Congress of Parkinson's Disease and Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that...

2013-06-13 08:28:04

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ -- NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under...

2013-06-03 08:26:49

NESS ZIONA, Israel, June 3, 2013 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease. These funds, part of the Foundation's 2013 Therapeutic Pipeline program, will support an upcoming phase 2 clinical trial with ND0612, a novel drug for the...

2013-06-02 23:00:52

Dopamine, the mood-enhancing hormone, might help give a memory boost, eReflect creator of Ultimate Memory announced today. A new study gives hope for better understanding of memory formation and how memory declines as people age. New York City, NY (PRWEB) June 03, 2013 Software company eReflect keeps track of all the latest research in memory science, to support and improve their self-improvement software, Ultimate Memory. As eReflect noted today, a new study under lead researcher Emrah...

Rats Get Depression In Spring Not Winter
2013-04-26 09:07:23

Alan McStravick for redOrbit.com - Your Universe Online Here in the latter days of April, much of the nation and the world is struggling to once and for all escape the cold grasp of the long arm of winter. For many, their mental health can be affected by the shorter hours of daylight. Whether you refer to the condition as the ℠winter blues´ or the ℠black dogs,´ or even the more formal title of ℠seasonal affective disorder´ (SAD), going for an extended...

2013-04-22 22:22:51

Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson's disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain. Parkinson's is a devastating neurodegenerative disorder caused by the death of dopamine neurons in a key motor area of the brain, the...

2013-04-15 08:30:37

NESS ZIONA, Israel, April 15, 2013 /PRNewswire/ -- NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula under development for continuous sub-cutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels in Parkinson's disease. In previous phase I...